Amar Biosystems’ Post

The clinical development pathway for mRNA vaccines and therapeutics differs in several important respects. Immunization requires only a minimal amount of protein production, as the immune system can markedly amplify the antigenic signal through cell-mediated and antibody-mediated immunity. In contrast, mRNA therapeutics require as much as a 1,000-fold-higher level of protein to reach a therapeutic threshold. Check out the comparative roadmap for mRNA vaccines VS. therapeutics here 🤗 Accelerate your research or discovery program with YXgene's cutting-edge mRNA technology platform, offering design, synthesis, and assay services: https://lnkd.in/ezc67GTf #mrna #mrnavaccines #medicine #mrnatherapy #biology #bioengineering Image from Nature

Here's a riddle for you: Who's the silent hero in protecting mRNA treatments such as the first-ever Covid-19 mRNA vaccines? 🧐 Answer: Lipids! They provide delicate mRNA molecules with a protective capsule and enable their safe and efficient transmission into cells. Without lipids, mRNA therapies wouldn't be possible. 🙏 @Merck KGaA, Darmstadt, Germany brought more than two decades of experience to provide definitive lipids to science to ensure these therapies continue. To combat the pandemic and manufacture protective doses of the vaccines, they expanded their already immense lipid production capacity. Want to know more about how lipid nanoparticles can transform the future of medicine? Check out the website. 👍 #humanprogress

FYI: 5 Advantages of mRNA Vaccines 1. Safety: No risk of evolution/resurgence, mutation/recombination, or integration into host genome. 2. Cellular Immune Response: More comprehensive, stronger and durable immune response. 3. Short R&D cycle: DNA sequence to mRNA/LNP only takes 2 months. 4. Easy to Scale Production: The mRNA manufacturing process does not involve cells, and one liter of IVT reaction can generate 100,000 doses. 5. Multivalent Vaccine Possible: Different mRNA sequences can be encapsulated in a single LNP. Have any questions on how to develop mRNA vaccines? We are happy to help you. Get in touch with us at sales@areterna.com #mRNA #vaccines #IVT #LNP

Excited to say our recent work on mRNA-LNPs for intramuscular delivery is out now as a preprint! This is the next chapter of the research authored by Julien Couture-Senécal and myself. This time, we report a strategy to dampen LNP-associated inflammation while maintaining mRNA vaccine responses. We describe how we designed a highly effective and more biodegradable ionizable lipid, and show that rapid clearance of the lipid lowers systemic inflammation. We're particularly proud of this work, and we hope that it spurs on new efforts to make more effective and tolerable mRNA vaccines! https://lnkd.in/erE8sH56

Really good summary of the #mRNA vaccine market, and future potential from genius writer, Dr. Cheryl Barton, published in pharmaphorum. Includes insightful expert contribution from Erik Digman Wiklund on the strengths and weaknesses of mRNA, how it fits within the wider #RNA and #genetherapy markets. Key quote "...we expect that linear mRNA will be superseded by circular mRNA because of its improved expression durability, longer shelf-life, and can be stored at higher temperatures,” explained Dr Wiklund. “In addition, circular mRNA vaccines will become significantly cheaper to produce, with up to 90% lower manufacturing cost, as they circumvent the need to use modified nucleotide analogues, and no 5´capping is required.” https://lnkd.in/epWtC5FN

mRNA drug offers hope for treating a devastating childhood disease To treat propionic acidaemia, which can be life threatening, hours-long infusions every two or three weeks of mRNA coding for two enzymes were given in doses hundreds of times greater than those of COVID-19 vaccines. Effects were impressive, and although the side effects were significant, they may have been due more to the disease than the treatment (although this assertion is questionable and needs confirmation). One commentator said “I’m just doubtful this is going to be a long-term therapy, I think it needs to be much less frequent dosing with better [nanoparticles] or more potent mRNA.” Maybe a DNA therapy would be more appropriate? https://lnkd.in/diC3EhCP

#rna #molecularbiology Using the #microbiome to improve the #immunogenicity of #messenger #rna based #vaccines 🅰️Lipid #nanoparticle-based #vaccines have achieved great success during the #Covid-19 pandemic. However, in order to improve specific immunity against an antigen and increase the expected effects after vaccination, there is still a need to optimize these particles. On the other hand, studies have shown that the microbiome and its metabolites, such as short-chain fatty acids (SCFA), are key mediators in the regulation of host #immunity, and their serum levels correlate with the response to #immunotherapy, especially In cancer patients, it is relevant; in such a way that they have beneficial effects on the host's immune system, especially in the induction of specific T cells against the antigen and the antibody response of B cells. 🅱️In the present study, #microbiome-derived lipid nanoparticles (mbmLNPs) have been developed to improve the immunogenicity of messenger RNA-based vaccines; In this way, propionate and butyrate fatty acids, in different ratios, were attached to the cholesterol of lipid nanoparticles. Using mbmLNPs particles, a #cancer #therapeutic vaccine (containing ovalbumin messenger RNA) and a COVID-19 vaccine (containing spike messenger RNA) were designed, and then their performance was compared with previous vaccines made with previously common lipid nanoparticles. 🆎In both in vitro (using cell lines) and in vivo (after injection into a laboratory animal) studies, partial replacement of cholesterol (25% cholesterol with fatty acid butyrate, B1-LNP) in the carrier, CD8+ T cell responses and It improved antigen-specific B cells. Also, the results showed that this partial replacement of cholesterol did not negatively affect the morphology and delivery efficiency of messenger RNA with lipid nanoparticles. ✅This study shows that #microbiome metabolites can be used as adjuvants to improve antigen-specific immune responses, alongside messenger RNA-based vaccines. More information 👇

🔊 #D2RProjectSpotlight: "Live imaging of mRNA 5′ cap interaction with translation initiation factors " led by Nahum Sonenberg, McGill University. Co-Investigators: Maria Vera Ugalde, PhD (McGill University) and Paul Wiseman (McGill University) Collaborator: Jacek Jemielity (University of Warsaw) This project aims to examine how individual proteins involved in translation interact with the mRNA cap in real-time inside cells. This information can help improve the effectiveness of future mRNA vaccines. 🔗 Learn more: https://buff.ly/4fNRWNp #DNA2RNA #Vaccine

I am excited to have completed a 2-day INTRODUCTORY mRNA VACCINE DESIGN AND DEVELOPMENT course organized by Helix Biogen Institute. mRNA vaccines are novel vaccines that work by directly delivering mRNA, encoding the specific protein antigen associated with a particular disease.   As compared to traditional vaccines, they are safe and flexible, can be rapidly developed as well as induce robust immune responses. The mRNA vaccine course exposed me to bioinformatics and artificial intelligence as important tools in the design of mRNA vaccines. I look forward to more training from Helix Biogen Institute on vaccine design and development. Special thanks to the facilitator Dr. Oladipo Elijah Kolawole (Ph.D) and his team for such a wonderful delivery! #mRNAVaccines #Bioinformatics #Vaccines #VaccineDesign #VaccineDevelopment #OneHealth #AfricanUnion #GlobalHealth

Background of Cap mRNA vaccines work by delivering mRNA that encodes for an antigen into human cells, where it is translated to produce the corresponding antigen protein, thereby inducing an effective immune response. The stability of mRNA, translation efficiency, and inherent immunogenicity are key to the success of mRNA as a therapeutic.